文献速递妇科

Gemogenovatucel-T(Vigil)维持免疫治疗:同源重组修复 proficient(HRP)卵巢癌的3年生存获益

Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer.
PubMed 文献 · Gynecol Oncol · 2021-10-23

本文报告了2b期VITAL研究(NCT02346747)中HRP卵巢癌患者接受Vigil或安慰剂维持治疗后的3年随访结果。Vigil组25例、安慰剂组20例,Vigil组3年总生存(OS)未达中位值,安慰剂组为26.9个月(HR 0.417,p=0.020);3年无复发生存(RFS)亦获益(分层HR 0.405,p=0.011),未观察到长期毒性。结论提示Vigil在HRP卵巢癌中具有持久活性,支持进一步评估。

要点

  • Vigil组3年OS未达中位,安慰剂组为26.9个月(HR 0.417,p=0.020)。
  • 3年RFS分层HR 0.405(p=0.011),Vigil组获益。
  • 未观察到Vigil长期毒性。

核心结论

  • Vigil在HRP卵巢癌患者中显示出对RFS和OS的持久活性,支持进一步评估。

研究设计与样本

  • 2b期、双盲、安慰剂对照VITAL研究(NCT02346747)的3年随访分析,HRP患者接受Vigil(n=25)或安慰剂(n=20)。

主要发现

  • Vigil组3年OS未达中位(95%CI 41.6个月至未达到),安慰剂组为26.9个月(95%CI 17.4个月至未达到),HR 0.417,p=0.020。
  • 3年RFS显示Vigil获益(分层HR 0.405,p=0.011)。
  • 未观察到Vigil长期毒性。
  • 从随机化时点起,Vigil组3年OS为70%,安慰剂组为40%(p=0.019)。
  • RMST分析OS显著(45.7 vs 32.8个月,p=0.008),RFS亦显著(p=0.025)。

临床怎么用

  • 对于BRCA野生型、HRP的卵巢癌患者,Vigil维持治疗可能带来OS和RFS获益,且未观察到长期毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Previously, Vigil demonstrated clinical benefit to prolong relapse free and overall survival in the BRCA wild-type (BRCA-wt), homologous recombination proficient (HRP) patient population. Here we provide long term follow up of 3 years in the HRP patient population enrolled in the Phase 2b VITAL study. METHODS: HRP patients treated with Vigil (n = 25) or placebo (n = 20) who were enrolled in the Phase 2b, double-blind, placebo-controlled (VITAL study, NCT02346747) were followed for safety, OS and RFS. OS and RFS from time of randomization (immediately prior to maintenance therapy) and from debulking tissue procurement time points were analyzed by Kaplan-Meier (KM) and restricted mean survival time (RMST) analysis. RESULTS: OS for Vigil treated patients at 3 years has not yet reached median OS time point (95% CI 41.6 months to not achieved) compared to 26.9 (95% CI 17.4 months to not achieved) in placebo treated patients (HR 0.417 p = 0.020). Three year RFS also showed benefit to Vigil (stratified HR 0.405, p = 0.011) and no long term toxicity to Vigil was observed. Three year OS for Vigil of 70% vs. 40% for placebo from time of randomization was observed (p = 0.019). RMST analysis was also significant for OS (45.7 vs. 32.8 months, p = 0.008) and RFS (p = 0.025). CONCLUSION: In conclusion, results suggest durable activity of Vigil on RFS and OS and support further evaluation of Vigil in HRP ovarian cancer.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Walter A, Rocconi RP, Monk BJ, et al. Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer. Gynecol Oncol. 2021. PMID: 34702567. doi:10.1016/j.ygyno.2021.10.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。